Recommendations on the medical management of aortic complications of Marfan's syndrome;Recommandations sur la prise en charge médicamenteuse des atteintes aortiques du syndrome de Marfan

Archives des Maladies du Coeur et des Vaisseaux

Volumn 99, Issue 5, 2006, Pages 540-546

  Jondeau, G ^a   Barthelet, M ^b   Baumann, C ^b   Bonnet, D ^b   Chevallier, B ^b   Collignon, P ^b   Dulac, Y ^b   Edouard, T ^b   Faivre, L ^b   Germain, D ^b   Van Kien, P Khau ^b   Lacombe, D ^b   Ladouceur, M ^b   Lemerrer, M ^b   Leheup, B ^b   Lupoglazoff, J M ^b   Magnier, S ^b   Muti, C ^b   Plauchu, H ^b   Raffestin, B ^b   Sassolas, F ^b   Schleich, J M ^b   Sidi, D ^b   Themar Noel C ^a   Varin, J ^a   Wolf, J E ^a   more..

^a HÔPITAL AMBROISE PARÉ   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; VERAPAMIL;

AORTA DISEASE; BETA ADRENERGIC RECEPTOR BLOCKING; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; EDITORIAL; HUMAN; MARFAN SYNDROME; MEDICAL PRACTICE; PATHOPHYSIOLOGY; SURVIVAL RATE; TREATMENT CONTRAINDICATION; AORTA ANEURYSM; ARTICLE; DISSECTING ANEURYSM; DRUG COMBINATION; FRANCE; MEDICAL SOCIETY; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANEURYSM, DISSECTING; AORTIC ANEURYSM; ATENOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FRANCE; HUMANS; MARFAN SYNDROME; SOCIETIES, MEDICAL; TREATMENT OUTCOME; VERAPAMIL;

EID: 33748743297     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Jondeau G, Boileau C, Chevallier B, et al. Syndrome de Marfan. Arch Mal Cœur Vaiss 2003;96:1081-8.
2. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004;36:855-60.
3. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-26.
4. Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med 1972;286:804-8.
5. Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. J Thorac Cardiovasc Surg 2002;123:360-1.
6. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol 1995;75:157-60.
7. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989;64:507-12.
8. Mart CR, Khan SA, Smith FC, Kavey RE. A new on-line method for predicting aortic root dilatation during two-dimensional echocardiography in pediatric patients with Marfan syndrome using the sinus of valsalva to annulus ratio. Pediatr Cardiol 2003;24:118-21.
9. Yin FC, Brin KP, Ting CT, Pyeritz RE. Arterial hemodynamic indexes in Marfan's syndrome. Circulation 1989;79:854-62.
10. Groenink M, de Roos A, Mulder BJ, et al. Biophysical properties of the normal-sized aorta in patients with Marfan syndrome: evaluation with MR flow mapping. Radiology 2001;219:535-40.
11. Nollen GJ, Groenink M, Tijssen JG, Van Der Wall EE, Mulder BJ. Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J 2004;25:1146-52.
12. Groenink M, de Roos A, Mulder BJ, Spaan JA, van der Wall EE. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998;82:203-8.
13. Shores J, Berger KR, Murphy EA, Pyerirz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330:1335-41.
14. Salim MA, Alpert BS, Ward JC, Pyeritz RE. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol 1994;74:629-33.
15. Rossi-Foulkes R, Roman MJ, Rosen SE, et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 1999;83:1364-8.
16. Rios AS, Silber EN, Bavishi N, Varga P, Burton BK, Clark WA, Denes P. Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J 1999;137:1057-61.
17. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation 2005;111:e150-7.
18. Elkayam U, Ostrzega E, Shotan A, Mehra A. Cardiovascular problems in pregnant women with the Marfan syndrome. Ann Intern Med 1995;123:117-22.